Búsqueda | Portal de Búsqueda de la BVS España

1.

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.

Araujo, D; Greystoke, A; Bates, S; Bayle, A; Calvo, E; Castelo-Branco, L; de Bono, J; Drilon, A; Garralda, E; Ivy, P; Kholmanskikh, O; Melero, I; Pentheroudakis, G; Petrie, J; Plummer, R; Ponce, S; Postel-Vinay, S; Siu, L; Spreafico, A; Stathis, A; Steeghs, N; Yap, C; Yap, T A; Ratain, M; Seymour, L.

Ann Oncol; 34(1): 48-60, 2023 01.

Artículo en Inglés | MEDLINE | ID: mdl-36182023

2.

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Goffin, J R; Nicholas, G; Mates, M; Tu, D; Chen, E; Laurie, S A; Juergens, R; Robinson, A; Goss, G; Reaume, M; Sun, S; Christink, K; Maize, C; MacFarlan, S; Sun, X; Ritter, H; Seymour, L; Bradbury, P A.

Invest New Drugs; 37(3): 498-506, 2019 06.

Artículo en Inglés | MEDLINE | ID: mdl-30317534

3.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz, M; Bogaerts, J; Calvo, E; Marabelle, A; Perrone, A; Seymour, L; Shalabi, A; Siu, L L; Tabernero, J; Giaccone, G.

Ann Oncol; 29(11): 2175-2182, 2018 11 01.

Artículo en Inglés | MEDLINE | ID: mdl-30202892

4.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein, V; Ellard, S L; Dent, S F; Tu, D; Mates, M; Dhesy-Thind, S K; Panasci, L; Gelmon, K A; Salim, M; Song, X; Clemons, M; Ksienski, D; Verma, S; Simmons, C; Lui, H; Chi, K; Feilotter, H; Hagerman, L J; Seymour, L.

Breast Cancer Res Treat; 167(2): 485-493, 2018 01.

Artículo en Inglés | MEDLINE | ID: mdl-29027598

5.

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Tsao, M-S; Le Teuff, G; Shepherd, F A; Landais, C; Hainaut, P; Filipits, M; Pirker, R; Le Chevalier, T; Graziano, S; Kratze, R; Soria, J-C; Pignon, J-P; Seymour, L; Brambilla, E.

Ann Oncol; 28(4): 882-889, 2017 04 01.

Artículo en Inglés | MEDLINE | ID: mdl-28137741

6.

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.

De Ruysscher, D; Lueza, B; Le Péchoux, C; Johnson, D H; O'Brien, M; Murray, N; Spiro, S; Wang, X; Takada, M; Lebeau, B; Blackstock, W; Skarlos, D; Baas, P; Choy, H; Price, A; Seymour, L; Arriagada, R; Pignon, J-P.

Ann Oncol; 27(10): 1818-28, 2016 10.

Artículo en Inglés | MEDLINE | ID: mdl-27436850

7.

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200.

Chu, Q S-C; Nielsen, T O; Alcindor, T; Gupta, A; Endo, M; Goytain, A; Xu, H; Verma, S; Tozer, R; Knowling, M; Bramwell, V B; Powers, J; Seymour, L K; Eisenhauer, E A.

Ann Oncol; 26(5): 973-981, 2015 May.

Artículo en Inglés | MEDLINE | ID: mdl-25632070

8.

Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.

Di, Y; Seymour, L; Fisher, K.

Gene Ther; 21(4): 440-3, 2014 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-24553347

9.

A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.

Chen, E X; Hotte, S; Hirte, H; Siu, L L; Lyons, J; Squires, M; Lovell, S; Turner, S; McIntosh, L; Seymour, L.

Br J Cancer; 111(12): 2262-7, 2014 Dec 09.

Artículo en Inglés | MEDLINE | ID: mdl-25393368

10.

The presence of KIR2DS5 confers protection against adult immune thrombocytopenia.

Seymour, L A; Nourse, J P; Crooks, P; Wockner, L; Bird, R; Tran, H; Gandhi, M K.

Tissue Antigens; 83(3): 154-60, 2014 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-24571473

11.

NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.

Dent, S F; Gelmon, K A; Chi, K N; Jonker, D J; Wainman, N; Capier, C A; Chen, E X; Lyons, J F; Seymour, L.

Invest New Drugs; 31(6): 1522-9, 2013 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-24072436

12.

RNAi-mediated knockdown of HMG CoA reductase enhances gene expression from physiologically regulated low-density lipoprotein receptor therapeutic vectors in vivo.

Hibbitt, O; Agkatsev, S; Owen, C; Cioroch, M; Seymour, L; Channon, K; Wade-Martins, R.

Gene Ther; 19(4): 463-7, 2012 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-21796214

13.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

Reiman, T; Lai, R; Veillard, A S; Paris, E; Soria, J C; Rosell, R; Taron, M; Graziano, S; Kratzke, R; Seymour, L; Shepherd, F A; Pignon, J P; Sève, P.

Ann Oncol; 23(1): 86-93, 2012 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-21471564

14.

Risk factors for persistent cervical intraepithelial neoplasia grades 1 and 2: managed by watchful waiting.

Ho, Gloria Y F; Einstein, Mark H; Romney, Seymour L; Kadish, Anna S; Abadi, Maria; Mikhail, Magdy; Basu, Jayasri; Thysen, Benjamin; Reimers, Laura; Palan, Prabhudas R; Trim, Shelly; Soroudi, Nafisseh; Burk, Robert D.

J Low Genit Tract Dis; 15(4): 268-75, 2011 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-21811178

15.

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

Goodwin, R; Ding, K; Seymour, L; LeMaître, A; Arnold, A; Shepherd, F A; Dediu, M; Ciuleanu, T; Fenton, D; Zukin, M; Walde, D; Laberge, F; Vincent, M; Ellis, P M; Laurie, S A.

Ann Oncol; 21(11): 2220-2226, 2010 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-20427348

16.

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).

Hirte, H; Oza, A; Swenerton, K; Ellard, S L; Grimshaw, R; Fisher, B; Tsao, M; Seymour, L.

Gynecol Oncol; 118(3): 308-12, 2010 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-20646751

17.

Factors influencing retention of adenovirus within tumours following direct intratumoural injection.

Bazan-Peregrino, M; Carlisle, R C; Purdie, L; Seymour, L W.

Gene Ther; 15(9): 688-94, 2008 May.

Artículo en Inglés | MEDLINE | ID: mdl-18288207

18.

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

Chi, K N; Ellard, S L; Hotte, S J; Czaykowski, P; Moore, M; Ruether, J D; Schell, A J; Taylor, S; Hansen, C; Gauthier, I; Walsh, W; Seymour, L.

Ann Oncol; 19(4): 746-51, 2008 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-18056648

19.

First Report of Infection of Poison Hemlock and Celery by Apium virus Y in Washington State.

Eastwell, K C; Glass, J R; Seymour, L M; Druffel, K J.

Plant Dis; 92(12): 1710, 2008 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-30764307

20.

Gene therapy targeting to tumor endothelium.

Bazan-Peregrino, M; Seymour, L W; Harris, A L.

Cancer Gene Ther; 14(2): 117-27, 2007 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-17096029

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: